Evox Therapeutics is a biotechnology startup that operates in the healthcare sector, specifically focusing on the development of exosome therapeutics. Exosomes are tiny vesicles that cells use to communicate with each other, and Evox is leveraging this natural delivery system to create treatments for serious, life-threatening rare diseases. These are conditions that currently have limited treatment options, making Evox's work potentially life-changing for patients and their families.

Evox's business model revolves around its proprietary DeliverEX™ platform, which combines the delivery capabilities of exosomes with targeting technology and advanced biomolecular engineering. This platform is used to develop a pipeline of therapeutics, both internally and in partnership with other companies. By partnering with other firms, Evox can both leverage their expertise and resources, and also provide them with access to its innovative technology.

The company's revenue comes from two main sources. First, from the development and eventual sale of its own therapeutics. Second, from partnerships with other companies who pay to use the DeliverEX™ platform or to co-develop therapeutics.

In summary, Evox Therapeutics is a pioneering biotech firm that's using its unique technology to create treatments for rare diseases. It operates in a niche but important market, and its business model combines internal development with strategic partnerships.

Keywords: Biotechnology, Healthcare, Exosome Therapeutics, Rare Diseases, DeliverEX™ Platform, Biomolecular Engineering, Drug Development, Strategic Partnerships, Life-threatening Diseases, Treatment Options.